The Hong Kong Association of the Pharmaceutical Industry Jan-Mar_13062014_110831.pdf · The Hong...
Transcript of The Hong Kong Association of the Pharmaceutical Industry Jan-Mar_13062014_110831.pdf · The Hong...
The Hong Kong Association of the
Pharmaceutical Industry
Issue 1 /3 2014 Jan - Mar 2014
In This Issue
46th Annual
General Meeting
HKAPI 45th
Annual Dinner
Forum on
Patient
Empowerment
for Diabetic
Patients
2014 Policy
Address and
2014-15 Budget
IFPMA Code
Workshop:
Hands-on
Compliance
Training
HKAPI 46th Annual General Meeting (Click here for more photographs)
HKAPI’s 46th Annual General Meeting was held on 24th March with the participation of
31 Full and Affiliate members and 6 Associate member companies. After confirming
the minutes of last year’s AGM, Dr Sian Ng, President, and Ms. Kelly Lam, Vice
President delivered the Board of Directors Report for the term 2012-2014, which
highlighted various initiatives undertaken by the Association in the key focus areas and
the progress we have made with the results achieved.
During the term of 2012-2014, the Board has identified through a member’s survey that
drug enlistment, drug access through subsidized programs, drug registration system,
code of practice and patent system are the key areas of focus. The HTA and
Enlistment Taskforce has been exchanging views with relevant stakeholders on the
development of HTA and ways to expedite the enlistment process. Seminars such as
PhRMA HTA Workshop and luncheons were also organized to enhance members’
understanding on HTA and the drug enlistment process.
Regarding drug safety and drug registration, HKAPI has been playing an active role in
working with the Drug Office on improving the efficiency of the drug registration system
and measures that safeguard drug quality and safety such as a code of practice for
wholesalers. From time to time, we also invited experts on various regulatory issues
such as pharmacovigilance, product quality assurance, biosimilar registration to share
with members and the health authority their experience in managing these regulatory
issues.
The HKAPI Code of Practice was revised last April and the Code of Practice Taskforce
worked on promoting the Code both internally to member companies through
members’ meetings and train the trainer workshop as well as externally to relevant
stakeholders such as healthcare professionals, patients groups and Government
departments.
First
Roundtable on
Rare Diseases
Policy in Hong
Kong
2014 CUHK
Career Fair
Editorial Board
Sabrina Chan
Jenny Wan
Contact Us
Tel: 2528-3061
Fax: 2865-6283
http://www.hkapi.hk/
The Board members and the Executive Director have continuously served on various
Government Bodies and Committees including the Pharmacy and Poison Board,
Business Facilitation Advisory Committee to provide our views on healthcare policies
and regulations. In the coming term, HKAPI will continue to focus our efforts on
improving drug accessibility, drug safety and working on the patient empowerment
program as well as promoting clinical trials and medical research in Hong Kong.
During the 46th Annual General Meeting, the following members were duly elected to
the Board for the term 2014-16.
President: Mrs. Rachel Frizberg (Roche)
Vice President: Dr. Sian Ng (Novartis)
Board members:
Ms. Joanne Fan (AbbVie)
Ms. Joanna Yao (Baxter)
Ms. Wyeman Tan (Eisai)
Mrs. Margaret Rumpf (GSK)
Mr. Richard Holloway (Medinova)
Ms. Geraldine Ip (Pfizer)
Ms. Kelly Lam (Sanofi-aventis)
Ms. Dora Mo (Takeda)
The HKAPI would like to take this opportunity to thank all the Board members as well
as all HKAPI member companies for their continuous support to the Association, in
particular, their participation in various Taskforces which have made tremendous
contributions to the work of the Association.
Dr. Sian Ng presented the President’s Report for
2013.
Ms. Kelly Lam talked about initiatives on drug
registration and patent system.
Ms. Sabrina Chan, HKAPI Executive Director,
chaired the 46th
AGM.
31 Full members and Affiliate members attended
the AGM and cast their votes.
Mr. Henry Wheare, Legal Advisor explained the
rules of the Board of Directors election and Mr.
Samuel Wong from BMS and Ms. Monique Lee
from Dechert were appointed as scrutineers.
Newly elected Board of Directors and our Honorary
Legal Advisor, Mr. Henry Wheare.
HKAPI 45th Annual Dinner (Click here for more photographs)
This year marks the 45th Anniversary of the establishment of the HKAPI. The HKAPI
Annual Dinner, a gala event of the industry, was held on the 15th January. The
Association was very honoured to have Professor John Leong, Chairman of the
Hospital Authority to join our celebration as the Guest of Honour and we were very
delighted by the presence of more than 250 distinguished guests including legislators,
consuls, government officials, healthcare professionals, pharmacists, scholars, friends
from patients’ organizations and HKAPI members.
The Annual Dinner started with the welcome address from Dr. Sian Ng, President of
HKAPI. In the speech, the importance of partnership and collaborations among all the
stakeholders in the delivery of high quality healthcare services was emphasized. Over
the years, the industry has been working closely with our partners in the areas of drug
innovation, drug safety, patient education as well as drug accessibility. With the
opening of the two Phase I Clinical Trials Centres in HKU and CUHK, the industry is
looking forward to more collaborations with the Government, and academic and
research institutes in the research of innovative medicines in Hong Kong. Regarding
patient education, the industry is very glad to have the opportunity to work with the
Hospital Authority, patients’ organizations on an empowerment program for diabetic
patients in Hong Kong, and our collaborations will certainly be extended to other
categories of chronic disease. On drug accessibility, we have been working closely with
the Drug Office and the Hospital Authority to improve the effectiveness of the
registration and enlistment system. The Association will continue to provide
constructive views to ensure patients have expedient and equitable access to
innovative and effective medicines.
Professor Leong, in his address, shared the three major missions that he would like to
achieve during his term of office, namely providing world-class and excellent medical
services to the Hong Kong citizens, provision of training to medical doctors and
providing a congenial environment for medical research and innovation. The Hospital
Authority appreciates the support from the industry in the implementation of various
initiatives that have enhanced the drug procurement systems and quality assurance.
More collaborative projects in areas such as clinical research, patient empowerment
program will be developed in future.
Ms. Kelly Lam, Vice President of HKAPI, gave the vote of thanks on behalf of the
Association. The industry is very thankful for the support from all the stakeholders in the
healthcare sector and our joint efforts with the Hospital Authority and Patients’ Groups
in improving drug safety and accessibility as well as patient education that will continue
definitely. The community of Hong Kong and all the stakeholders can be assured of the
continued support from the pharmaceutical industry in the provision of effective and
quality healthcare services.
Following the toasting and cake cutting, we had great performance from our
partners in healthcare: Tai Chi performed by patients and a nurse in diabetes
mellitus, a cappella performed by Medi-pella, singing performance from Mr. and
Mrs. Chan Kwok Wa, Dr. Alan Ng, Dr. Tse Hung Hing, Dr. Henry Yeung, Professor
Joyce You, Dr. Joseph Lee. The enjoyable evening ended with the HKAPI Board of
Directors singing together with our guests from the Hospital Authority.
Last but not least, we would like to express our sincere thanks to the Hong Kong Tourism
Board for sponsoring the drumming performance, the Annual Dinner organizing
committee led by Ms. Wyeman Tan, Board of Directors and our members’ tremendous
support.
The Board of Directors welcomed Prof. John Leong,
Chairman of the Hospital Authority, Dr. Cheung
Wai-lun, Director (Cluster Services) and Ms. Margaret
Cheung, Head of Corporate Services.
Dr. Sian Ng, President of HKAPI, delivered the
welcome speech.
Our Guest of Honour, Professor Leong delivered his
speech at the 45th Anniversary Annual Dinner.
Ms. Kelly Lam, Vice President of HKAPI, delivered
the vote of thanks.
Drumming performance sponsored by the Hong Kong
Tourism Board.
Singing performed by Mr. and Mrs. Chan Kwok Wa.
Tai Chi performed by patients and a nurse in diabetes
mellitus.
A cappella performed by members of Medi-pella:
Dr. Jeff Pong, Dr. Aziz Kam, Mr. Jack Wan, Dr.
Victor Yeung and Dr. Alan Ng.
Ms. Wyeman Tan, Board of Directors and Dr. Alan Ng
singing duets.
Prof. John Leong and colleagues from the Hospital
Authority were invited on stage.
Forum on Patient Empowerment for Diabetic Patients (Click here for
more photographs)
On 18th January, 2014, the Hong Kong Alliance of Patients’ Organization, the Hospital
Authority and the HKAPI joined hands to organize a Forum on Patient Empowerment
for Diabetic Patients. The program aims to gather both local and overseas experts’
opinions on the direction and strategies for empowering diabetic patients and their
carers in the disease’s management.
Site visits to both public and private healthcare service providers of diabetic care and
patient empowerment program were arranged between 16-17th January for the
participants to understand the current services provided to diabetic patients in Hong Kong
and the empowerment programme provided by various non-government organizations.
The opening ceremony was officiated by Professor Sophia Chan, JP., Under Secretary
for Food and Health. Government of the HKSAR, Professor John Leong, Chairman of the
Hospital Authority, Mr. SL Yuen, Chairman of the Hong Kong Alliance of Patients'
Organizations and Dr. Sian Ng, President of HKAPI.
During the forum, overseas speakers Prof. Ruth Colagiuri, Director of Health &
Sustainability Unit, Menzies Centre for Health Policy, the University of Sydney as well as
Prof. Robert Anderson from the Department of Medical Education, University of Michigan
Medical School, shared with the audience their experience on patient empowerment and
education in Australia and the United States.
In the subsequent roundtable discussion, overseas experts, healthcare professionals,
specialist nurses in diabetes mellitus as well as representatives from non-government
organizations, patient groups, as well as pharmaceutical industry, presented and
exchanged views on strategies for the effective prevention, treatment and disease
management of diabetes in Hong Kong. The valuable recommendations and suggestions
generated from the forum will be consolidated for formulating the policy direction for
diabetic care in Hong Kong.
The HKAPI would like to thank the following member companies for supporting and
co-organizing the event.
Boehringer Ingelheim (HK) Ltd
Bristol-Myers Squibb Pharma (HK) Limited
Eli Lilly Asia Inc
Janssen, a division of Johnson & Johnson (HK) Ltd
Merck Sharp & Dohme (Asia) Ltd
Novartis Pharmaceuticals (HK) Ltd
sanofi-aventis Hong Kong Limited
Takeda Pharmaceuticals Hong Kong Limited
Officiating guest: Professor Sophia Chan, JP., Under
Secretary for Food and Health. Government of the
HKSAR.
Officiating guest: Professor John Leong, Chairman
of the Hospital Authority.
Officiating guest: Mr. SL Yuen, Chairman of the HK
Alliance of Patients' Organizations.
Dr. Sian Ng extended a warm welcome to all the
distinguished guests and participants of the Forum.
Prof. Robert Anderson and Prof. Ruth Colagiuri
shared their overseas experience on patient
empowerment.
Ms. Joyce Chiu of Eli Lilly, member of the program
committee, shared the industry’s experience on
diabetic patient education.
H
Ms. Kelly Lam, HKAPI Vice President delivered the
closing remarks.
Over 200 participants attended the Patient
Empowerment Forum.
2014 Policy Address and 2014-15 Budget
The Policy Address for 2014 was presented on 15th January followed by the delivery of
the Budget 2014-15 by the Financial Secretary on 26 February. The following links
provide details on the key policies and budget proposed on the public and private
healthcare services.
http://www.policyaddress.gov.hk/2014/eng/p71.html
http://www.budget.gov.hk/2014/eng/budget35.html
Before the formulation of the Policy Address, the Chief Secretary and the Food and
Health Bureau have invited the Association to provide our views on healthcare policy. In
our views, the government should further expedite the accessibility of new drugs in the
public healthcare system in Hong Kong through the following measures:
1. To review if the current administrative meetings and procedures other than scientific
evaluation in the drug registration process are necessary and beneficial. We believe
the drug registration process shall be based on scientific evaluation and should not
be delayed by administrative procedures.
2. Hong Kong should take reference from advanced overseas countries to develop an
effective process for introducing drugs for rare disease, including a simplified drug
registration procedure and enlistment in the HA drug formulary to enhance drug
accessibility for patients with rare diseases.
3. To extend the subsidized list of drugs in programmes such as Samaritan Fund and
Community Care Fund to cover more drug items and relax the clinical guidelines for
prescribing new and effective drugs so that patients can have effective treatment as
early as possible to increase the cure rate as well as improving their quality of life.
IFPMA Code Workshop: Hands-on Compliance Training
On 31st March, IFPMA organized the Code Workshop: Hands-on Compliance Training in
Manila. Ms. Sabrina Chan, Executive Director of HKAPI was invited to be a training
facilitator to share with the participants cases and hands-on experience in relation to
interactions with healthcare professionals. Sabrina also presented the key challenges
and achievements in healthcare promotion and communication in the subsequent Forum
on Ethical Business Practices: Fostering Integrity and Good Governance in the
Healthcare Sector.
Ms. Sabrina Chan was invited as a panel presenter at the Forum on Ethical Business Practices.
First Roundtable on Rare Diseases Policy in Hong Kong
Organized by the Hong Kong Alliance of Patients’ Organizations and supported by
various rare disease concern groups and members of HKAPI, the first Roundtable on
Rare Diseases Policy in Hong Kong was held on 27th February. The Roundtable brought
together overseas and local experts to share their views and experience in formulating a
rare disease policy. Prof. Li Ding-guo, Chairman, Rare Disease Specialty Society,
Shanghai Medical Association presented on the development of rare diseases policy in
China and the difficulties they encountered, illustrated with his experience in Shanghai.
Dr. Gu Hyun Min, Head of Information Management of Korea Orphan Drug Center,
discussed the orphan drug policy in South Korea and the role and organization of Korea
Orphan Drug Center. Dr. Lee Koon Hung, Chief Manger (Cluster Performance), Hospital
Authority shared with the audience the current system and challenges in treating public
patients with uncommon disorders.
In the second part of the event, two panel discussions were held, one from the medical
perspective and the other from the angle of patients’ suffering from rare diseases. The
panellists from the medical group, which include a pathologist, a paediatrician, a
pharmacist and clinicians, gave their views on the definition of rare diseases, how to
increase public awareness and physician knowledge on rare disease, the screening of
new-borns for rare diseases and the establishment of a database in Hong Kong.
The discussants from the patient panel include patients with rare diseases, carers,
nurse, social worker, representatives from organizations providing rehabilitation
services and special education. Patients and their carers talked about the problems they
face in the diagnosis and treatment of the rare disease, rehabilitation and voiced out the
medical, social and community support they need from the Government.
The presentations and discussions from the Roundtable has provided a lot of insights on
how to enhance the development of rare disease policy in Hong Kong.
Representatives from the supporting organizations
of the Roundtable.
Overseas and local speakers of the Roundtable.
Panel discussion from the medical perspective, led
by Prof. Lam Ching Wan, HKU (Second from the
right).
Panel discussion from patients’ perspective, led by
Mr. KP Tsang, Hong Kong Alliance of Patients’
Organizations.
HA Briefing to Pharmaceutical Manufacturers and Supplier
2014 CUHK Career Fair
The Career Fair of the Chinese University of Hong Kong was held on 24 January. This
year, six HKAPI members, including Baxter Healthcare Ltd, Merck Sharp & Dohme
(Asia) Ltd, Novartis Pharmaceuticals (HK) Limited, Pfizer Corporation Hong Kong Ltd,
Roche Hong Kong Limited, sanofi-aventis Hong Kong Limited, supported and
participated in the booth exhibition and recruitment talk. The aim of the Career Fair is
to enable students to have a more in-depth understanding of the R&D-based
pharmaceutical companies in Hong Kong through face to face meeting.
During the talk, each member company introduced the background and organization of
their company, the responsibilities and the career prospect of different job functions
such as regulatory affairs, medical, sales and marketing. The presenters also shared
with the audience how they can find the right career and plan their career path. About
80 undergraduate and postgraduate students attended the recruitment presentation
session.
Mr. Walter Yung, Sanofi-Aventis Hong Kong Ltd. Ms. Rebecca Cheng, Baxter Healthcare Ltd.
Mr. Simon Yung, Merck Sharp & Dohme (Asia) Ltd.
Mr. Maukee Chan, Novartis Pharmaceuticals (HK)
Ltd.
Mr. Andy Mok, Roche Hong Kong Ltd.
Ms. Eugenia Ng, Pfizer Corporation HK Ltd.
Booth exhibition of HKAPI member companies.
Both undergraduate and postgraduate students
attended the recruitment presentation session.